Silence Therapeutics (SLN) Net Income towards Common Stockholders (2024 - 2026)
Silence Therapeutics (SLN) reported Net Income towards Common Stockholders of -$15.0 million for Q1 2026, up 47.57% on a YoY basis from -$10.1 million in Q1 2025, and down 27.08% sequentially from -$11.8 million in Q4 2025.
Silence Therapeutics (SLN) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Silence Therapeutics (SLN) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$15.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 47.57% year-over-year to -$15.0 million; the trailing twelve-month figure through Mar 2026 stood at -$75.0 million (down 25.98% YoY), and the FY2025 full-year result was -$88.6 million, down 195.45% from the prior year.
- Net Income towards Common Stockholders fell to -$15.0 million in Q1 2026, from -$11.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $24.3 million in Q4 2024 to a low of -$35.5 million in Q3 2024.
- A 3-year average of -$15.2 million and a median of -$19.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders sank 1134.0% in 2025 and surged 47.57% in 2026, its largest moves.
- Tracing SLN's Net Income towards Common Stockholders over 3 years: stood at $24.3 million in 2024, then tumbled by 148.51% to -$11.8 million in 2025, then retreated by 27.08% to -$15.0 million in 2026.
- Business Quant data shows SLN's Net Income towards Common Stockholders at -$15.0 million in Q1 2026, -$11.8 million in Q4 2025, and -$21.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Silence Therapeutics | 1.59 Bn | 1.45 Bn | 411,000.00 | -14.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.96 Mn |
| Dec 31, 2025 | -11.77 Mn |
| Sep 30, 2025 | -20.96 Mn |
| Jun 30, 2025 | -27.35 Mn |
| Mar 31, 2025 | -28.53 Mn |
| Dec 31, 2024 | 24.26 Mn |
| Sep 30, 2024 | -35.54 Mn |
| Jun 30, 2024 | -19.76 Mn |
| Mar 31, 2024 | -2.31 Mn |